Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (691-700 of 869) with videos related to

Pageof 87
Sort By:
Blood|December 18, 2015
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cellsMichele Cea, Antonia Cagnetta, Sophia Adamia, et al.
Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Blood|September 20, 2014
Differential and limited expression of mutant alleles in multiple myelomaNaim U Rashid, Adam S Sperling, Niccolo Bolli, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Blood Advances|November 8, 2018
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Nickolas Tsakmaklis, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
Blood|October 20, 2005
Antimyeloma activity of heat shock protein-90 inhibitionConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Lenalidomide and rituximab in Waldenstrom's macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Blood|March 6, 2023
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myelomaYao Yao, Jessica Fong Ng, Woojun Daniel Park, et al.
Pageof 87

Showing results (691-700 of 869) with videos related to

Sort By:
Pageof 87
Blood|December 18, 2015
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cellsMichele Cea, Antonia Cagnetta, Sophia Adamia, et al.
Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Blood|September 20, 2014
Differential and limited expression of mutant alleles in multiple myelomaNaim U Rashid, Adam S Sperling, Niccolo Bolli, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Blood Advances|November 8, 2018
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Nickolas Tsakmaklis, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
Blood|October 20, 2005
Antimyeloma activity of heat shock protein-90 inhibitionConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Lenalidomide and rituximab in Waldenstrom's macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Blood|March 6, 2023
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myelomaYao Yao, Jessica Fong Ng, Woojun Daniel Park, et al.
Pageof 87